Millendo braces for deep cuts after its last clinical effort ends in defeat and a last search for a way to end things
05 Jan 2021
Acquisition
Turn out the lights, the party is over at Millendo Therapeutics.
Nine months after pulling the plug on a pivotal study of their lead drug, the Ann Arbor, MI-based biotech is shuttering its sole remaining early-stage study for their NK3R antagonist MLE-301. And they’re sounding a bleak note, planning some deep cuts for the remaining staff while the board goes about the business of finding a way to gain some value out of this for shareholders.
At the top of the alternative strategies on the table: A sale or merger of the company, or what’s left of it.
The biotech is washing its hands of a drug aimed at treating menopausal vasomotor symptoms. After looking over the results from their dose-ascending Phase I, researchers found little reason to remain optimistic — especially given the competitive landscape of NK3R drugs.
This is the drug Millendo — long helmed by Julia Owens — turned to after its Phase IIb trial for livoletide went belly up last spring.
The stock $MLND, which has erased virtually all of its once high-flying value, dropped 14% Tuesday morning,
Company chairman Carol Gallagher summed it up in a statement:
Organizations
Indications
-Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.